Showing 241 - 260 results of 29,313 for search '(( 5 ((((non decrease) OR (point decrease))) OR (nn decrease)) ) OR ( 50 a decrease ))', query time: 0.67s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244
  5. 245

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  6. 246
  7. 247
  8. 248
  9. 249

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the recurrence group, BCVA (logMAR) showed no significant improvement over time: 0.37 ± 0.20 preoperatively and 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p = 0.45). In contrast, the non-recurrence group demonstrated significant and sustained improvement from 0.31 ± 0.25 preoperatively to 0.25 ± 0.25, 0.23 ± 0.26, 0.23 ± 0.28, 0.21 ± 0.27, 0.20 ± 0.30, and 0.16 ± 0.30 at corresponding postoperative time points (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g005" target="_blank">Fig 5</a>).…”
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259

    Nemp1 supports NE openings in erythroblasts. by Didier Hodzic (132944)

    Published 2022
    “…Ery A, B, and C were distinguished based on increasing Ter119 intensity and decreasing nuclear diameter (7.4, 6.4, and 5.4 μm for EryA, B, and C, respectively). …”
  20. 260